文献速递产科母胎医学

IVF妊娠先心病产前筛查策略的成本效果分析

Cost-effectiveness of prenatal screening methods for congenital heart defects in pregnancies conceived by in-vitro fertilization.
PubMed 文献 · Ultrasound Obstet Gynecol · 2021-05-05

该决策分析模型从社会视角比较三种IVF妊娠先心病筛查策略:解剖超声异常后选择性胎儿超声心动图、仅ICSI后常规胎儿超声心动图、所有IVF后常规胎儿超声心动图。结果显示解剖超声策略成本最低且QALY略低,其余策略ICER远超支付意愿阈值,常规胎儿超声心动图不具成本效果。

要点

  • IVF妊娠先心病筛查首选解剖超声异常后选择性胎儿超声心动图。
  • 对所有IVF妊娠常规胎儿超声心动图不具成本效果。
  • 每额外检出1例重大先心病,强化筛查成本约为新生儿首年照护费用的5倍。

核心结论

  • IVF妊娠先心病筛查最成本效果策略为详细解剖扫描发现心脏异常后再行胎儿超声心动图。
  • 对所有IVF妊娠常规胎儿超声心动图不具成本效果。

研究设计与样本

  • 决策分析模型,社会视角,从受孕至产后1年。
  • 比较解剖超声、仅ICSI后胎儿超声心动图、所有IVF后胎儿超声心动图三种策略。

主要发现

  • 平均成本:解剖超声8119美元,仅ICSI 8408美元,所有IVF 8560美元。
  • 效果:解剖超声1.74487 QALYs,仅ICSI 1.74497 QALYs,所有IVF 1.74499 QALYs。

关键数值与推荐

  • 强化筛查所有IVF妊娠每额外检出1例重大先心病的社会成本约为新生儿首年照护费用的5倍。

临床怎么用

  • 对IVF妊娠先心病筛查,优先采用详细解剖超声,仅在发现心脏异常时行胎儿超声心动图。
  • 不建议对所有IVF妊娠常规行胎儿超声心动图。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine if a policy of universal fetal echocardiography (echo) in pregnancies conceived by in-vitro fertilization (IVF) is cost-effective as a screening strategy for congenital heart defects (CHDs) and to examine the cost-effectiveness of various other CHD screening strategies in IVF pregnancies. METHODS: A decision-analysis model was designed from a societal perspective with respect to the obstetric patient, to compare the cost-effectiveness of three screening strategies: (1) anatomic ultrasound (US): selective fetal echo following abnormal cardiac findings on detailed anatomic survey; (2) intracytoplasmic sperm injection (ICSI) only: fetal echo for all pregnancies following IVF with ICSI; (3) all IVF: fetal echo for all IVF pregnancies. The model initiated at conception and had a time horizon of 1 year post-delivery. The sensitivities and specificities for each strategy, the probabilities of major and minor CHDs and all other clinical estimates were derived from the literature. Costs, including imaging, consults, surgeries and caregiver productivity losses, were derived from the literature and Medicare databases, and are expressed in USA dollars ($). Effectiveness was quantified as quality-adjusted life years (QALYs), based on how the strategies would affect the quality of life of the obstetric patient. Secondary effectiveness was quantified as number of cases of CHD and, specifically, cases of major CHD, detected. RESULTS: The average base-case cost of each strategy was as follows: anatomic US, $8119; ICSI only, $8408; and all IVF, $8560. The effectiveness of each strategy was as follows: anatomic US, 1.74487 QALYs; ICSI only, 1.74497 QALYs; and all IVF, 1.74499 QALYs. The ICSI-only strategy had an incremental cost-effectiveness ratio (ICER) of $2 840 494 per additional QALY gained when compared to the anatomic-US strategy, and the all-IVF strategy had an ICER of $5 692 457 per additional QALY when compared with the ICSI-only strategy. Both ICERs exceeded considerably the standard willingness-to-pay threshold of $50 000-$100 000 per QALY. In a secondary analysis, the ICSI-only strategy had an ICER of $527 562 per additional case of major CHD detected when compared to the anatomic-US strategy. All IVF had an ICER of $790 510 per case of major CHD detected when compared with ICSI only. It was determined that it would cost society five times more to detect one additional major CHD through intensive screening of all IVF pregnancies than it would cost to pay for the neonate's first year of care. CONCLUSION: The most cost-effective method of screening for CHDs in pregnancies following IVF, either with or without ICSI, is to perform a fetal echo only when abnormal cardiac findings are noted on the detailed anatomy scan. Performing routine fetal echo for all IVF pregnancies is not cost-effective. © 2020 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Chung EH, Lim SL, Havrilesky LJ, et al. Cost-effectiveness of prenatal screening methods for congenital heart defects in pregnancies conceived by in-vitro fertilization. Ultrasound Obstet Gynecol. 2021. PMID: 32304621. doi:10.1002/uog.22048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。